The ACY1 Knockout SK-HEP-1 Polyclonal Cells product is a heterogeneous population of SK-HEP-1 cells generated by CRISPR/Cas9-mediated disruption of the ACY1 gene. This polyclonal knockout pool provides a versatile loss-of-function model for studying aminoacylase 1 (ACY1) function, as it contains a mixture of edited cells with diverse mutations introduced at the target locus. Unlike clonally derived cell lines, the polyclonal format captures the complexity of gene editing outcomes and is suitable for bulk population analyses, including metabolic profiling and functional genomics screens.
The host cell line, SK-HEP-1, is a widely used hepatic adenocarcinoma cell line originally established from the ascites of a patient with liver cancer. SK-HEP-1 cells exhibit a hybrid phenotype with both epithelial and endothelial markers, making them a unique model for studying tumor cell plasticity and hepatic drug metabolism. Their utility in liver cancer research, combined with a moderate proliferation rate and robust in vitro growth characteristics, establishes them as a suitable platform for generating gene-edited derivatives aimed at dissecting metabolic and oncogenic pathways.
ACY1 encodes aminoacylase 1, a cytosolic homodimeric enzyme that catalyzes the hydrolysis of N-acylated amino acids into free L-amino acids and acetate. This reaction plays a critical role in amino acid metabolism, providing a salvage mechanism for acylated amino acids released during protein degradation and turnover. The enzyme??s activity is primarily regulated by substrate availability, and its expression may be modulated by hepatic transcription factors. Downstream, the products L-amino acids and acetate integrate into central metabolic pathways, including the urea cycle and nitrogen metabolism, thereby linking ACY1 function to broader amino acid homeostasis.
In the context of SK-HEP-1 cells, disruption of ACY1 provides a valuable tool for investigating amino acid salvage pathways and metabolic vulnerabilities inherent to hepatic adenocarcinoma. The knockout model enables researchers to assess how loss of deacetylase activity influences the intracellular pool of N-acetylated amino acids and their downstream metabolic fate. Given the importance of amino acid metabolism in cancer cell proliferation and redox balance, the ACY1 polyclonal knockout can be used to explore metabolic dependencies and potential therapeutic targets relevant to liver cancer.
This polyclonal knockout product supports a wide range of experimental applications, including western blotting and RT-qPCR for confirming loss of ACY1 expression, aminoacylase activity assays to quantify enzymatic function, and mass spectrometry-based metabolic profiling of N-acetylated amino acids. It is particularly suited for disease modeling of aminoacylase 1 deficiency, a rare inborn error of metabolism associated with neurological abnormalities, as well as functional genomics studies probing the role of amino acid salvage in cancer biology. For additional details, custom orders, or technical support, please contact Ascent Research.
